Alzheimer's disease research at the University of Michigan is getting a $10 million boost: a major grant that will fund a broad array of efforts aimed at finding and fighting the causes of the diseas
Researchers in the laboratory of Boston College Chemistry Professor John T. Fourkas have demonstrated the fabrication of microscopic polymeric structures on top of a human hair. Fourkas, in collaboration with Boston Coll
Neuroscientists at Frenchay hospital in Bristol have discovered that an experimental drug for Parkinson's disease has been shown to trigger new nerve growth in the brain,
Researchers at Bath University are disputing the common belief that women are able to tolerate pain better than men; they claim that in fact the opposite is true.They say that while women feel
Disruption of a single gene, Nrf2, plays a critical role in determining the susceptibility to asthma. A research team led by
More tests need to be prescribed to save and prolong the lives of Canadians living with coronary artery disease, says a study released from the University of Alberta. The research shows that t
By wearing a unique weighted back support device and participating in a special exercise program, women over 60 with osteoporosis-caused curvature of the spine improved their balance and experienced diminished back pain, giving researchers at
A new analysis based on animal studies suggests that showering in manganese-contaminated water for a decade or more could have permanent effects on the nervous system. The damage may occur even at levels of manganese considered safe by the
When encouraged to use memorization strategies commonly employed by healthy individuals, people with schizophrenia can be helped to remember information just as well as their healthy counterparts, a process that in itself seems to spur a normalization
For the first time, researchers have demonstrated in separate short-term trials that a single drug therapy may be effective in treating both the manic and depressive phases of bipolar disorder.The condition (bipolar I and II) affects approximat
Published in the April 28, 2005 issue of the journal Nature, the study in mice and lab cultures of immune cells called macrophages showed that a protein called I-kappa-B kinase alpha (IKKa) is responsible for terminating an inflammatory response before it can damage cells and organs.
Senior author Michael Karin, Ph.D., UCSD professor of pharmacology, explained that IKKa is part of a sophisticated two-punch system that maintains a proper inflammatory response. While it is well known that IKKa's sister protein, IKK beta (IKKb), initiates the inflammatory response, little was known about the mechanism for stopping the response before it injures tissue, such as the damage that occurs in chronic bacterial and parasitic infections like tuberculosis and leprosy, or in autoimmune disorders like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus (SLE).
Karin's team, which was the first to identify the IKK protein complex in 1996, determined in this new investigation that both IKKa and IKKb are activated at the same time following a microbial infection. While IKKb initiates the inflammatory response by causing the degradation of inhibitory proteins called IkBs, IKKa interacts with two additional proteins - RelA and C-Rel - which move into the nucleus of the cell after the IkBs are degraded. After being "tagged" by IKKa in the cytoplasm of the cell, RelA and c-Rel bind to genes that mediate the inflammatory response. But their life is limited - the IKKa-mediated "tag" ensures that RelA and c-Rel will bind to their target genes for only a short duration. Once RelA and c-Rel are removed from their target genes, the inflammatory response is terminated.
"This is very important for a proper inflammatory response in infection and immunity," Karin said. "The inflammatory response involves the production of potentially toxic mediators, so it is important that inflammation be allowed to do its work rapidly, but only transiently."
The new findings also have implications for disorders such as flesh-eating staph infections and drug-resistant bacterial infections that are difficult to treat. The researchers note that in these cases, it might be possible to develop an inhibitor of IKKa that boosts the inflammatory response to better fight these infections. However, such an inhibitor should have a short half-life, so that its potential devastating effect can be properly terminated.
The Karin lab, which has made several of the past discoveries involving IKKb's pro-inflammatory role, has also studied IKKa over the years, but they have identified roles unrelated to the primary inflammatory response. For example, in 2001, the investigators determined that IKKa was essential for formation of the skin's outer layer.* In a follow-up study, the team found clues that IKKa may be more involved in the immune response than they previously thought, but its role still appeared limited.** The current study is the first, however, to specifically show the novel mechanisms used by the protein to control the duration of an inflammatory response.
The study was funded by the National Institutes of Health. The co-first authors were Toby Lawrence, Ph.D., and Magali Bebien, Ph.D., post-doctoral fellows in the Laboratory of Gene Regulation and Signal Transduction, UCSD Department of Pharmacology. Currently, Lawrence is an assistant professor and member of the Faculty of Medicine, Imperial College London. Additional authors were George Liu, Ph.D., UCSD Division of Pediatric Infectious Diseases, UCSD School of Medicine; and Victor Nizet, M.D., associate professor of pediatrics, UCSD School of Medicine.
http://health.ucsd.edu/